

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Purified anti-human CD38 (Maxpar(R) Ready)

RRID:AB_2562819

Type: Antibody

Proper Citation

BioLegend Cat# 303535, RRID:AB_2562819

Antibody Information

URL: http://antibodyregistry.org/AB_2562819

Proper Citation: BioLegend Cat# 303535, RRID:AB_2562819

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF®

Antibody Name: Purified anti-human CD38 (Maxpar(R) Ready)

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: Clone HIT2

Antibody ID: AB_2562819

Vendor: BioLegend

Catalog Number: 303535

Record Creation Time: 20231110T035220+0000

Record Last Update: 20260829T220716+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD38 (Maxpar(R) Ready).

No alerts have been found for Purified anti-human CD38 (Maxpar(R) Ready).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Balke-Want H, et al. (2026) c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. Cell reports. Medicine, 7(1), 102549.

Klysz DD, et al. (2024) Inosine induces stemness features in CAR-T cells and enhances potency. Cancer cell, 42(2), 266.

Gerassy-Vainberg S, et al. (2024) A personalized network framework reveals predictive axis of anti-TNF response across diseases. Cell reports. Medicine, 5(1), 101300.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer cell, 42(1), 35.

Toh J, et al. (2024) Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Cell reports. Medicine, 5(12), 101851.

Yousuf S, et al. (2023) Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer. Gastroenterology, 165(4), 891.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 185(5), 916.

Labanieh L, et al. (2022) Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell, 185(10), 1745.

McIlwain DR, et al. (2021) Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell host & microbe, 29(12), 1828.